Study aims to boost genetic testing in pancreatic cancer families
NCT ID NCT03762590
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study looks at whether different ways of teaching families about genetics can increase the number of people who get tested for inherited mutations linked to pancreatic cancer. Up to 1,000 adult family members of pancreatic cancer patients will be enrolled. Participants may provide a saliva sample for FDA-approved genetic testing, and researchers will compare two education methods to see which one works better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2019
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individual who is 18 years or older * Individual who has signed the informed consent * Individual with: --A first-degree relative who has (or had) pancreatic ductal adenocarcinoma (PDAC) OR a second-degree relative who has (or had) PDAC and has a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53 * The germline mutation and history of PDAC must be on the maternal side or paternal side of the individual's family * Individual with a valid United States mailing address * Individual with access to a healthcare provider and is willing to share genetic test results with that provider/the study team Exclusion Criteria: * Individual with a known cancer susceptibility gene * Individual who has received genetic counseling for cancer risk within the last 3 years * Individual who has received a bone marrow transplant, who has had a blood transfusion within the last 7 days, or who has an active hematologic malignancy (i.e. leukemia or lymphoma) * Individual who is unable to sign the informed consent because of mental incompetency or psychiatric illness * Individual who is unwilling to complete baseline and follow-up questionnaires * Individual who has a life expectancy of less than 1 year * Individual with only APC I1307K mutation within their family * Individual with only PMS2 exons 12-15 deletion mutation within their family
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Candidates for hereditary pancreatic cancer testing are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States